Market Eyes LivePfizer Inc. (PFE) Stock Rating & Analysis
MELANY's data-driven read on Pfizer Inc. · Pharmaceutical Preparations.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. Once a maker of many types of healthcare products and chemicals, it now derives most sales from prescription drugs and vaccines, with top sellers including the pneumococcal vaccine Prevnar 13 and the cardiology drugs Vyndaqel and Eliquis; it sells globally, with international sales 40% of the total and emerging markets a major contributor.
Why PFE scores 68/100
MELANY scores Pfizer Inc. 68/100 by weighing eight factors. Here is how PFE breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 9.6x, earnings growth accelerating
- FCF yield 7.9%
Margins, returns on capital, and balance-sheet strength.
- Gross margin 75%
Direction and relative strength of the recent share-price trend.
- Price +9.8% above 50-day MA
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +16%
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for PFE
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Pfizer Inc. sits in the Healthcare sector theme, which MELANY currently rates 42/100 for strength. Theme strength feeds PFE's momentum and catalyst factors above.
PFE trade plan (members only)
MELANY has a full position plan for Pfizer Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates PFE
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Pfizer Inc.'s 68/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about PFE
Is Pfizer Inc. (PFE) a buy?
As of 2026-08-21, MELANY rated Pfizer Inc. Favorable with a composite score of 68/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Pfizer Inc.'s MELANY score?
Pfizer Inc. (PFE) has a MELANY composite score of 68/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the PFE stock rating calculated?
MELANY scores PFE from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Pfizer Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Pfizer Inc. (PFE) Favorable with a composite of 68/100 as of 2026-08-21. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the PFE stock price forecast?
MELANY does not publish price targets or forecasts for PFE. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 68/100 across eight factors for Pfizer Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is PFE stock overvalued or undervalued?
MELANY's valuation factor currently reads 64/100 for Pfizer Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives PFE's read.
What price should I buy PFE at?
Rather than chasing the current price, MELANY computes a smart entry zone for PFE: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying PFE stock?
The top risks MELANY currently flags for Pfizer Inc.: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Pfizer Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 67/100 for Pfizer Inc., and earnings track record, at 100/100. The 68/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will PFE stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 55/100 for PFE right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this PFE rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-21. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores PFE continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
PFE's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.